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Abstract
Background: In recent years, a number of tools have been developed to explore microRNAs (miRNAs) by
analyzing their target genes. However, a reverse problem, that is, inferring patterns of protein-coding genes
through their miRNA regulators, has not been explored. As various miRNA annotation data become available,
exploring gene patterns by analyzing the prior knowledge of their miRNA regulators is becoming more feasible.
Results: In this study, we developed a tool, miR2Gene, for this purpose. Various sets of miRNAs, according to prior
rules such as function, associated disease, tissue specificity, family, and cluster, were integrated with miR2Gene. For
given genes, miR2Gene evaluates the enrichment of the predicted miRNAs that regulate them in each miRNA set.
This tool can be used for single genes, multiple genes, and KEGG pathways. For the KEGG pathway, genes with
enriched miRNA sets are highlighted according to various rules. We confirmed the usefulness of miR2Gene
through case studies.
Conclusions: miR2Gene represents a novel and useful tool that integrates miRNA knowledge for protein-coding
gene analysis. miR2Gene is freely available at http://cmbi.hsc.pku.edu.cn/mir2gene.
Background
MicroRNAs (miRNAs) are a class of small non-coding
RNAs acting as negative gene regulators by binding to
the 3’UTR of target mRNAs through base pairing at the
post-transcriptional level [1]. Approximately over one
third of all genes in the human genome could be regu-
lated by miRNAs [2]. During the past few years, a num-
ber of bioinformatics tools have been developed to infer
miRNA insights through integrative analysis of miRNAs
and their targets [3-7]. These tools help improve our
understanding of miRNAs. However, to our knowledge,
tools that infer the patterns of protein-coding genes by
analyzing the miRNAs that regulate the relevant pro-
tein-coding genes are currently unavailable. In recent
years, the rapid development of various experiments
involving miRNAs has dramatically increased knowledge
regarding these regulators. For example, according to
the Human microRNA Disease Database (HMDD,
http://cmbi.bjmu.edu.cn/hmdd), which manually inte-
grates experimentally supported miRNA-disease associa-
tions, the number of reported miRNA-disease
associations is quite limited before 2002, but was
increased dramatically in recent years, specifically up to
2507 miRNA-disease associations, including 440 distinct
miRNA genes and 247 diseases, as stored as of January
2011 [8]. We previously confirmed the usefulness of the
prior knowledge for mining novel miRNA patterns for
desired miRNAs from biological experiments [9-11].
Meanwhile accumulating knowledge of these regulators
makes it possible to explore hidden patterns of protein-
coding genes by analyzing the miRNAs that regulate
these genes however no such tools are currently
available.
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miR2Gene integrates miRNAs into various miRNA sets
according to rules from prior knowledge, such as func-
tion, associated disease (HMDD), family, cluster, and tis-
sue specificity. For the given genes, miR2Gene then
integrates miRNAs that regulate them and performs
enrichment analysis of the predicted miRNA regulators
in each predefined miRNA set. The tool then provides
the significant miRNA sets, which care the potential pat-
terns of the given genes. Currently, miR2Gene can ana-
lyze one single gene, multiple genes, and the KEGG
pathways (http://www.genome.jp/kegg/). Finally, we con-
firmed the usefulness of miR2Gene through case studies.
Methods
miR2Gene summary
The whole workflow of miR2Gene is shown in Figure 1.
For the given protein-coding genes, miR2Gene first pre-
dicts the miRNAs that regulates them using different
miRNA-target prediction algorithms (TargetScan [2],
MicroCosm [12], and DIANA-microT [13]). Then,
miR2Gene evaluates the enrichment of the predicted
miRNA regulators of the given genes in the predefined
miRNA sets. After submitting a task, the results are
shown in a new page. For different tasks (single genes,
multiple genes, and KEGG pathways), exact procedures
have some differences. A tutorial page is provided to
make miR2Gene user-friendly. For each specific task, a
Figure 1 Scheme of the miR2Gene analysis pipeline.
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cific analysis page.
Input data
When a specific task, such as analysis of one single
gene, multiple genes, or one KEGG pathway is selected,
the user needs to enter specific input data for the speci-
fic task. For single or multiple genes, the user needs to
f i r s ti n p u tt h eg e n en a m eo rI Df o rt h es p e c i f i cg e n e
identifiers. Currently, miR2Gene supports seven types of
gene identifiers, such as the Official Gene Symbol,
Entrez Gene ID, Ensembl Gene ID, Ensembl Transcript
ID, UCSC gene ID, Refseq mRNA ID, and GeneBank
Accession Number. For multiple genes, they should be
arranged in one column and each row represents only
one gene. We provide one parameter “set the threshold
value” for the analysis of multiple genes. The threshold
means that only the miRNAs that regulate no less than
the “threshold” of given genes are considered in later
analysis. For both single gene analysis and multiple gene
analysis, the user can view the predicted miRNA regula-
tors in the corresponding analysis pages. For the KEGG
pathway analysis, the user needs to select the desired
KEGG pathway first, and then determine whether to
analyze the pathway genes individually or analyze them
as a whole. The next procedure for all three types of
tasks is selecting a method to predict the miRNAs that
regulate the given protein-coding genes. miR2Gene pro-
vides three choices, namely, TargetScan [2], MicroCosm
[12], and DIANA-microT [13] for predicting the
miRNA regulators. We downloaded the TargetScan pre-
dictions (version 5.1) from http://www.targetscan.org/,
the MicroCosm predictions (version 5) from http://
www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/
, and the DIANA-microT predictions (version 3.0) from
http://diana.cslab.ece.ntua.gr/microT.
Enrichment analysis of predefined miRNA sets to the
predicted regulatory miRNAs for given genes
We used the hypergeometric test to determine the sig-
nificant enrichment of each miRNA set for the predicted
regulatory miRNAs for the given genes, as we previously
described [9]. The hypergeometric test generates the sig-
nificance (P-value) and calculates the fold of enrichment
for each miRNA set. The fold value is calculated by
dividing the actual with the expected number of pre-
dicted miRNAs matched in corresponding miRNA set.
The percentage of matched miRNAs in the correspond-
ing miRNA set is also given. Considering that miR2-
Gene analyzes multiple miRNA sets for the same input
dataset, two methods for multiple comparison correc-
tion, Bonferroni and FDR, are provided to correct the
original P-values.
Outputs
The result of the desired task is shown in a new page. For
analyzing single genes or multiple genes, the miRNA sets
that have at least one match in the predicted miRNAs are
shown. The miRNA sets are arranged in five categories,
namely Cluster, Family, Function, HMDD (miRNA-asso-
ciated diseases), and TissueSpecific (miRNA tissue speci-
ficity, which was obtained from the study of Lu et al. [8]).
The miRNA functional set were manually curated from
literature. We obtained the miRNA family set and
miRNA cluster set from the miRBase database [14]. The
user can rank the results by Count (number of matched
miRNAs), Percent (percentage of matched miRNAs in
corresponding miRNA set), Fold (the actual matched
number/expected matched number), P-value, Bonferroni
(Bonferroni-corrected P-value), and FDR (FDR-corrected
P-value). The significantly enriched miRNA sets are con-
sidered as putatively associated with the given protein-
coding gene(s). One important point that the user should
remember is that the discovered pattern in the Function
category could be sometimes reversed because of the
inverse regulatory relationship between the given genes
and their miRNA regulators.
For the analysis of the KEGG pathways, the result
page shows three panels. The left panel lists the signifi-
c a n te n r i c h e d( F D R ≤0.05) miRNA sets arranged in dif-
ferent categories and ranked by significance. The middle
panel lists all genes included in the input KEGG path-
way. The right panel is the figure presentation of the
pathway. Clicking any miRNA set in the left panel with
highlight the corresponding genes significantly regulated
by the miRNA set in the pathway figure at the right
panel. The two buttons in them i d d l ep a n e lc a ns h o w
(highlight) or hide all genes that have at least one signif-
icantly enriched miRNA set. Clicking any gene listed in
the middle panel will list all significantly enriched
miRNA sets associated with the selected gene. The
miR2Gene provides links to KEGG.
Results
To confirm the usefulness of miR2Gene in gene pattern
discovery, we chose the gene “ABL2” and the KEGG
pathway “cell cycle” as examples for tasks of single gene
and pathway analyses. Analysis of multiple genes is simi-
lar with that of single gene analysis.
For analysis of ABL2, miR2Gene found that the pre-
dicted miRNAs (obtained by TargetScan) that regulate
ABL2 are significantly enriched in Cluster mir-302a
(FDR = 3.37×10
-3), mir-181c (FDR = 0.04), and mir-
106b (FDR = 0.05), Family let-7, mir-30, mir-17, mir-15,
mir-181, mir-302, mir-148, and mir-25. Among these
miRNA sets, some of them are well known to be asso-
ciated with cancer, i.e. let-7 family and mir-17 cluster
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significant miRNA sets include Function miRNA tumor
suppressors (FDR = 5.87×10
-8), anti-cell proliferation
(FDR = 2.74×10
-7), human embryonic stem cell (FDR =
1.29×10
-6), hormones regulation (FDR = 2.63×10
-4), cell
cycle (FDR = 2.64×10
-4), folliculogenesis (FDR =
3.51×10
-3), onco-miRNAs (FDR = 5.28×10
-3), granulo-
poiesis (FDR = 6.36×10
-3), immune response (FDR =
7.80×10
-3), bone regeneration (FDR = 0.01), apoptosis
(FDR = 0.03) and cell proliferation (FDR = 0.05). The
analysis in the HMDD category showed that 76% (26/34)
of the significant diseases is cancer (Additional File 1).
These results indicate that ABL2 is strongly related with
cancer. Furthermore, the miRNA sets “miRNA tumor
suppressors” is among the top significant sets. Because
miRNAs mainly negatively regulate target genes, the
above result suggests that ABL2 may act mainly as an
oncogene. Indeed, according to the annotation of NCBI
(http://www.ncbi.nlm.nih.gov/), ABL2 is a member of the
Abelson family of nonreceptor tyrosine protein kinase
genes and is v-abl Abelson murine leukemia viral onco-
gene homolog 2. Interestingly, almost all of the currently
reported ABL2-associated cancers have been identified
successfully through miR2Gene analysis, including mela-
noma [15] (FDR = 9.13×10
-9, rank No.1 in all diseases by
miR2Gene), lymphoma [16] (FDR = 4.23×10
-3)a n dl e u -
kemia [17,18] (FDR = 1.10×10
-3). Analysis also showed
that ABL2 is strongly associated with digestive system
cancer (FDR = 3.54×10
-5), which is further supported by
two studies that found ABL2 is involved in gastrointest-
inal stromal tumors (GISTs) [19,20]. miR2Gene did not
directly identify GISTs because GISTs-associated miR-
NAs are not presently reported. Therefore, these data are
not integrated with miR2Gene. Overall, the results show
a high accuracy of miR2Gene prediction, suggesting that
miR2Gene is a useful tool for gene pattern discovery.
Non-cancer diseases showing strong significance through
miR2Gene analysis include heart failure (FDR = 4.91×10
-
8, rank No. 4), Schizophrenia (FDR = 2.07×10
-4), and
autistic disorder (FDR = 5.47×10
-3). Although no study
provides evidence for the associations of these disease
and ABL2, ABL2 may be a potential molecule associated
with these diseases. Interestingly, ABL2 has a role in the
KEGG ErbB signaling and viral myocarditis pathways,
both of which are associated with heart function, suggest-
ing that ABL2 has a role in heart function and could
therefore be associated with heart failure. For the pre-
dicted functions, most of them, except for cancer-asso-
ciated functions do not have direct evidences although
several have some indications. For example, the function
“granulopoiesis” could be supported indirectly by its
well-known involvement in leukemia.
For the cell cycle pathway analysis, miR2Gene pre-
dicted that the mir-302 cluster is the most significant
miRNA cluster and the mir-15 family is the most signifi-
cant miRNA family. Indeed, mir-302 cluster was actually
confirmed to be induced by Oct4/Sox2 and it regulates
multiple cell cycle regulators. Inhibition of mir-302
causes human embryonic stem cells to accumulate in the
G1 phase [21]. The mir-15 family, also known as the mir-
16 family, was also confirmed to induce cell cycle arrest
by regulating several cell cycle genes [22]. Various types
of cancers occupy the top significant locations of the
HMDD category, suggesting that cell cycle pathway is
strongly related with cancer. The only non-cancer disease
among the top locations is heart failure. Moreover, the
heart-specific miRNA set is shown as the most significant
set in the TissueSpecific category. These results suggest
that heart function is also strongly associated with the
cell cycle. The “cell cycle” miRNA set is one of the most
significant sets in the Function category (rank No. 2). Fig-
ure 2 shows more details regarding the cell cycle-related
miRNAs involved in the regulation of the cell cycle path-
way. The miR2Gene shows that multiple genes in the cell
cycle pathway are significantly preferred to be regulated
by the cell cycle-related miRNA set. This result was con-
firmed by Carleton et al., who noted that some genes in
the cell cycle pathway such as cyclin protein, CDK6/4,
CDK2, E2F, CDC, WEE1 and CHEK1 are miRNA targets
and their interactions are involved in cell cycle regulation
[23]. miR2Gene also shows that miRNAs seem to take
part more in the G1 phase (Figure 2). Although the
miR2Gene prediction result on the cell cycle pathway
needs further experimental confirmation and support,
the new patterns provide new insights into the cell cycle
through miRNAs.
Discussion
By enrichment analysis of miRNAs that regulate the
given gene, miR2Gene is able to mine patterns of the
given protein-coding genes. Therefore, miR2Gene repre-
sents a novel tool in this topic. The results showed that
this tool is useful. However, limitations exist in this tool.
The major limitation is that currently the data of
miRNA set is limited, which may result to bias in the
analysis. Another limitation is that the prediction of
miRNA-target pairs has high false positives and high
false negatives. This also may produce bias in the analy-
sis. We believe that as more miRNA sets are collected
and more accurate miRNA-target prediction tools
becomes available, miR2Gene would produce more reli-
able result.
Conclusions
In recent years, tools have been developed to infer bio-
logical insights of miRNAs through integrative analysis
of miRNAs and their targets. However, tools for the
reverse problem, that is, inferring the biological
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regulators are not available because of the limited
prior knowledge regarding miRNAs. Considering that a
majority of protein-coding genes are putative targets of
miRNAs, exploring novel patterns of protein-coding
genes through integrative analysis of the miRNAs that
regulate them has become increasingly interesting. As
prior knowledge regarding miRNAs is accumulating
rapidly, developing tools for the above purpose is
becoming more feasible. In this study, we developed a
tool, miR2Gene, to address this problem. For given
protein-coding genes, miR2Gene first predicts the miR-
NAs that regulate the input genes and then performs
enrichment analysis of the predefined miRNA knowl-
edge in the predicted miRNAs. miR2Gene supports
three types of analysis, namely single genes, multiple
genes, and KEGG pathways. Moreover, the usefulness
of miR2Gene has been confirmed through two case
studies. Currently, miR2Gene is only used for human
genes and pathways, but can easily be extended to
other species when sufficient miRNA prior knowledge
becomes available.
Additional material
Additional File 1: miRNA sets that are significantly enriched in the
miRNAs that are predicted to regulate ABL2 and their statistical
results.
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Figure 2 The cell cycle pathway and the significant genes on cell cycle-related miRNAs. The genes whose miRNA regulators are significantly
enriched in the cell cycle-related miRNA set are highlighted in yellow.
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